Latest Breaking News On - Focus area approach - Page 16 : comparemela.com

Astellas invests $50m to support advancement of Poseida s cancer cell therapy

Astellas invests $50m to support advancement of Poseida s cancer cell therapy
pmlive.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from pmlive.com Daily Mail and Mail on Sunday newspapers.

Mark gergenAdam pearsonAstellas pharmaPoseida therapeuticsFocus area approachRoche therapeutics

Astellas and Poseida Therapeutics Announce Strategic Investment to Support Poseida s Commitment to Redefining Cancer Cell Therapy

Poseida is a clinical-stage biotechnology company dedicated to advancing a new class of cancer cell therapy and gene therapy products using genetic engineering technologies Astellas to invest a total of $50 million to acquire approximately 8.8% of Poseida and to receive a right of exclusive negotiation and first refusal for any potential partnering of P-MUC1C-ALLO1, an allogeneic CAR-T cell therapy product candidate for solid tumors Astellas will have the right to designate an obser.

Naoki okamuraMark gergenAdam pearsonPoseida therapeutics incExchange commissionAstellas pharma incSupport poseidaRedefining cancer cellPoseida boardPoseida therapeuticsFocus area approachAstella primary focusesChief strategy officerChief executiveSite specific gene editingLooking statements

Astellas and Poseida Therapeutics Announce Strategic Investment to Support Poseida s Commitment to Redefining Cancer Cell Therapy

Poseida is a clinical-stage biotechnology company dedicated to advancing a new class of cancer cell therapy and gene therapy products using genetic engineering technologies Astellas to invest a.

Mark gergenAdam pearsonNaoki okamuraExchange commissionPrnewswire astellas pharma incAstellas pharma incPoseida therapeutics incPoseida boardPoseida therapeuticsFocus area approachAstella primary focusesChief strategy officerChief executiveSite specific gene editing systemLooking statementsPrivate securities litigation reform act

Iveric Bio Receives U S FDA Approval for IZERVAY™ (avacincaptad pegol intravitreal solution), a New Treatment for Geographic Atrophy

/PRNewswire/ Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura, "Astellas"), today announced the U.S. Food and Drug Administration (FDA).

United statesNaoki okamuraPravinu dugelIveric bioArshadm khananiAstellas companyClinical research at sierra eye associatesAstellas pharma incDrug administrationFoundation fighting blindnessAstellas pharmaClinical researchSierra eye associatesChief executive officerFoundation fightingPrescribing information

Iveric Bio Receives U S FDA Approval for IZERVAY™ (avacincaptad pegol intravitreal solution), a New Treatment for Geographic Atrophy - Astellas Pharma (OTC:ALPMY)

IZERVAY is the only approved GA treatment with a statistically significant reduction in the rate of GA progression at the 12-month primary endpoint across two Phase 3 clinical trials IZERVAY slowed loss of photoreceptors

United statesArshadm khananiIveric bioPravinu dugelNaoki okamuraDrug administrationAstellas pharma incClinical research at sierra eye associatesAstellas companyFoundation fighting blindnessAstellas pharmaClinical researchSierra eye associatesChief executive officerFoundation fightingPrescribing information